Study, year of publication Study treatment Comparators CE ratio CE ratio IFX Ananthakrishnan et al., 2011 [19 ] IFX (tailored) Antibiotics Dominated Dominated IFX (upfront) Antibiotics $2,757,857/QALY $3,121,546/QALY Ananthakrishnan et al., 2013 [20 ] IFX (MTN or dose escalation) IFX (dose escalation) $49,278/QALY $55,776/QALY Blackhouse et al. , 2012 [21 ] IFX Std care $222,955/QALY (CAD 2011) $229,197/QALY Bodger et al., 2009 [22 ] IFX (1 year tx) Std care £19,050/QALY $49,290/QALY IFX (2 year tx) Std care £21,300/QALY $55,112/QALY Doherty et al., 2012 [23 ] IFX AZA/6MP $1,831,912/QALY $2,073,493/QALY Dretzke et al., 2011 [24 ] IFX IND (severe disease) Std care Dominant Dominant IFX MTN (severe disease) Std care £68,315/QALY $157,706/QALY IFX MTN (severe disease) IFX IND (severe disease) £5,030,000/QALY $11,611,849/QALY IFX IND (moderate disease) Std care £94,321/QALY $217,741/QALY IFX MTN (moderate disease) Std care £317,991/QALY $734,088/QALY IFX MTN (moderate disease) IFX IND (moderate disease) £13,900,000/QALY $32,088,410/QALY Jaisson-Hot et al., 2004 [25 ] IFX (retreatment with relapse or no response) Std care (including surgery) €63,700.82/QALY $122,252/QALY IFX MTN Std care (including surgery) €784,057.49/QALY $1,504,736/QALY Kaplan et al., 2007 [26 ] IFX (increasing dose) ADA $332,032/QALY $426,928/QALY Lindsay et al., 2008 [27 ] IFX (luminal CD) Std care £26,128/QALY $60,316/QALY IFX (fistulizing CD) Std care £29,752/QALY $68,683/QALY Punekar et al., 2010 [28 ] IFX Std care £14,607/QALY $37,794/QALY Steenholdt et al., 2014 [29 ] Individualised therapy (serum IFX and IFX antibody levels using the proposed algorithm) IFX dose intensification Dominant Dominant Steenholdt et al., 2015 [30 ] Individualised therapy (serum IFX and IFX antibody levels using the proposed algorithm) IFX dose intensification Dominant Dominant Tang et al., 2012 [31 ] IFX ADA Dominant Dominant IFX Certolizumab Pegol Dominant Dominant IFX NAT Dominant Dominant Velayos et al., 2013 [32 ] Testing-based strategy (IFX) Dose escalation Dominant Dominant ADA Blackhouse et al. , 2012 [21 ] ADA Std care $193,305/QALY (CAD2011) $198,717/QALY ADA IFX $451,165/QALY (CAD 2011) $463,797/QALY Bodger et al., 2009 [22 ] ADA (1 year tx) Std care £7,190/QALY $18,603/QALY ADA (2 year tx) Std care £10,310/QALY $26,676/QALY CADTH, 2008 [33 ] ADA Std care $113,034/QALY (CAD 2008) $128,067/QALY ADA IFX Dominant Dominant Dretzke et al., 2011 [24 ] ADA IND (severe disease) Std care Dominant Dominant ADA MTN (severe disease) Std care £7,749/QALY $17,888/QALY ADA MTN (severe disease) ADA MTN £4,980,000/QALY $11,496,423/QALY ADA IND (moderate disease) Std care Dominant Dominant ADA MTN (moderate disease) Std care £160,079/QALY $369,545/QALY ADA MTN (moderate disease) ADA IND (moderate disease) £13,900,000/QALY $32,088,410/QALY Loftus Jr et al., 2009 [34 ] ADA (severe disease) Std care £16,064/QALY $38,195/QALY ADA (moderate-to-severe disease) Std care £33,731/QALY $80,202/QALY Yu et al., 2009 [35 ] ADA MTN IFX MTN Dominant Dominant IFX + AZA Marchetti et al., 2013 [36 ] IFX + AZA (top-down strategy) Steroid (step-up strategy) Dominant Dominant Saito et al., 2013 [37 ] IFX + AZA IFX £24,917/QALY $57,051/QALY Other biologics (GOL, NAT, VED) Ananthakrishnan et al., 2012 [38 ] NAT Certolizumab Pegol $381,678/QALY $432,011/QALY Immunosuppressants (AZA, 6MP, cyclosporine) Ananthakrishnan et al., 2011 [19 ] AZA Antibiotics Dominated Dominated Doherty et al., 2012 [23 ] AZA/6MP No therapy $299,188/QALY $338,643/QALY Priest et al., 2006 [39 ] AZA MTX Dominant Dominant AZA No immunosuppressant therapy Dominant Dominant
